Sermorelin

A message to the pituitary

Sermorelin is a laboratory-made version of the first part of growth hormone-releasing hormone. The natural hormone carries a message from the brain to the pituitary gland, the small gland that releases growth hormone. Sermorelin follows that signalling route; it is not growth hormone in another package.

That distinction has a practical limit. A substance that asks the pituitary to release a hormone depends on the gland still being able to make it. It does not replace a missing capacity. The medical question is broader than wanting a higher number on a blood test.

An older medical history, with a narrow scope

Sermorelin once had U.S. approvals for testing the pituitary’s growth-hormone response and for certain growth problems in children. Those approvals ended in 2009. The FDA’s later withdrawal determination records that the older products were not withdrawn from sale for reasons of safety or effectiveness.

That finding does not make today’s preparations FDA-approved, and the earlier uses were not approvals for adult recovery or sleep. There is no current FDA-approved sermorelin product on the U.S. market. Compounded sermorelin is not FDA-approved, even when prepared under the rules applying to patient-specific pharmacy care.

Why sleep enters the conversation

The body’s growth-hormone release rises and falls in pulses and is closely tied to sleep. A human sleep study examined the relationship between sleep onset, deep sleep and the overnight hormone pattern. This helps explain the interest in the signal, rather than establishing that a peptide preparation changes your night for the better.

Small studies in older adults have measured hormone responses to sermorelin or related substances. They are not a large evidence base for recovery. A study of a modified related peptide found no change in sleep quality. That was a related substance, not sermorelin itself, so we keep both the negative finding and the difference in identity in view.

More deep sleep, a higher hormone measurement and less soreness are three different outcomes. One cannot be assumed from another. Your own experience of a tiring week cannot identify a hormone deficiency, either. Diagnosis requires a clinical assessment, rather than an inference from a familiar symptom.

What remains uncertain about safety

Older studies reported flushing and discomfort where injections were given, and some participants developed antibodies, immune proteins that recognize a substance. There is no current FDA-reviewed sermorelin label providing a modern account of risks in every group or information about pregnancy.

Long-term use for general wellness is not well characterized. Blood sugar, fluid retention and growth-related signalling are relevant questions for a provider, particularly when other conditions or medicines are involved. A claim that the body releases its own hormone does not resolve those uncertainties.

A review is about the reason for treatment

Promise Peptides offers a U.S. provider-review path for sermorelin. A licensed provider considers each request, including whether treatment is appropriate at all. Not everyone qualifies. What is available depends on your state and the treatment under review.

Compounded sermorelin is not FDA-approved. The provider decides whether any prescription is appropriate and what assessment or follow-up belongs with it. An adult’s recovery goal is not the same situation as the childhood growth problems in the older research. A careful discussion needs to state the purpose of treatment and what evidence supports that purpose.

The 2026 anti-doping list names sermorelin as prohibited at all times. That matters separately from a prescription decision for anyone subject to sport testing. You can also return to the sleep guide for the distinction between a normal overnight signal and evidence for changing it.